Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer

被引：148
|
作者：
Hong, Shaodong [1 ,2 ,3 ]
Gao, Fangfang [1 ,2 ,3 ]
Fu, Sha [4 ]
Wang, Yan [5 ]
Fang, Wenfeng [1 ,2 ,3 ]
Huang, Yan [1 ,2 ,3 ]
Zhang, Li [1 ,2 ,3 ]
机构：
[1] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[2] Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Dept Pathol, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[5] Quest Genom, Nanjing, Jiangsu, Peoples R China
来源：
JAMA ONCOLOGY | 2018年 / 4卷 / 05期
基金：
国家重点研发计划;
关键词：
CHEMOTHERAPY; METAANALYSIS; IMPACT;
D O I：
10.1001/jamaoncol.2018.0049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：739 / 742
页数：5
相关论文
共 50 条
  • [31] EGFR tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer
    Kowalski, D. M.
    Krzakowski, M.
    Jaskiewicz, P.
    Janowicz-Zebrowska, A.
    Glogowski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors
    Karachaliou, Niki
    Rosell, Rafael
    ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (03) : 114 - 117
  • [33] Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    周清
    魏雪武
    高欣
    何韵婷
    杨潇蓉
    Science Foundation in China, 2019, 27 (01) : 72 - 80
  • [34] Epidermal growth factor receptor tyrosine kinase inhibitors - Application in non-small cell lung cancer
    Thomas, M
    CANCER NURSING, 2003, 26 (06) : 21S - 25S
  • [35] Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
    Hammerman, Peter S.
    Jaenne, Pasi A.
    Johnson, Bruce E.
    CLINICAL CANCER RESEARCH, 2009, 15 (24) : 7502 - 7509
  • [36] Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)
    Usui, Kazuhiro
    Yokoyama, Takuma
    Naka, Go
    Ishida, Hiroo
    Kishi, Kazuma
    Uemura, Kohei
    Ohashi, Yasuo
    Kunitoh, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (06) : 554 - 558
  • [37] Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors
    Chen, Yu-Mu
    Lai, Chien-Hao
    Rau, Kun-Ming
    Huang, Cheng-Hua
    Chang, Huang-Chih
    Chao, Tung-Ying
    Tseng, Chia-Cheng
    Fang, Wen-Feng
    Chen, Yung-Che
    Chung, Yu-Hsiu
    Wang, Yi-Hsi
    Su, Mao-Chang
    Huang, Kuo-Tung
    Liu, Shih-Feng
    Chen, Hung-Chen
    Chang, Ya-Chun
    Chang, Yu-Ping
    Wang, Chin-Chou
    Lin, Meng-Chih
    LUNG CANCER, 2016, 98 : 99 - 105
  • [38] Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors for Treatment of Malignant Pleural Effusion in EGFR-Mutant Lung Adenocarcinoma Patients
    Lee, K.
    Chung, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [39] Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
    Gao, Yuan
    Song, PingPing
    Li, Hui
    Guo, HongBo
    Jia, Hui
    Zhang, BaiJiang
    ONCOTARGETS AND THERAPY, 2016, 9 : 13 - 20
  • [40] Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
    Jassem, Jacek
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S387 - S390
12345